Toxicologic Pathology Forum: Opinion on Not Euthanizing Control Animals in the Recovery Phase of Non-Rodent Toxicology Studies

Author:

Janardhan Kyathanahalli S.12ORCID,Sura Radhakrishna3,Salian-Mehta Smita3,Flandre Thierry4ORCID,Palazzi Xavier5ORCID,Zane Doris3,Singh Bhanu3,Jacob Binod2,Hukkanen Renee Rosemary6ORCID,Al-Haddawi Muthafar7,Bennet Bindu8,Laast Victoria9ORCID,Lee Donna10,Peterson Richard1,Romeike Annette11,Schorsch Frederic12,Guffroy Magali1ORCID

Affiliation:

1. AbbVie, Inc., North Chicago, Illinois, USA

2. Merck & Co., Inc., Rahway, New Jersey, USA

3. Gilead Sciences, Inc., Foster City, California, USA

4. Novartis, Basel, Switzerland

5. Pfizer, Groton, Connecticut, USA

6. Eisai, Inc., Cambridge, Massachusetts, USA

7. Bristol Myers Squibb, New Brunswick, New Jersey, USA

8. Magenta Therapeutics, Cambridge, Massachusetts, USA

9. Labcorp Early Development Laboratories Inc., Madison, Wisconsin, USA

10. Genentech, San Francisco, California, USA

11. Labcorp Early Development Services GmbH, Muenster, Germany

12. Bayer SAS, Sophia-Antipolis, France

Abstract

Nonclinical toxicology studies that are required to support human clinical trials of new drug candidates are generally conducted in a rodent and a non-rodent species. These studies typically contain a vehicle control group and low, intermediate, and high dose test article groups. In addition, a dosing-free recovery phase is sometimes included to determine reversibility of potential toxicities observed during the dosing phase and may include additional animals in the vehicle control and one or more dose groups. Typically, reversibility is determined by comparing the test article–related changes in the dosing phase animals to concurrent recovery phase animals at the same dose level. Therefore, for interpretation of reversibility, it is not always essential to euthanize the recovery vehicle control animals. In the absence of recovery vehicle control tissues, the pathologist’s experience, historical control database, digital or glass slide repositories, or literature can be used to interpret the findings in the context of background pathology of the species/strain/age. Therefore, in most studies, the default approach could be not to euthanize recovery vehicle control animals. This article provides opinions on scenarios that may or may not necessitate euthanasia of recovery phase vehicle control animals in nonclinical toxicology studies involving dogs and nonhuman primates.

Publisher

SAGE Publications

Subject

Cell Biology,Toxicology,Molecular Biology,Pathology and Forensic Medicine

Reference21 articles.

1. U.S. Department of Health and Human Services, Food and Drug Administration. M3(R2) nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals. Accessed July 6, 2021. https://www.fda.gov/media/71542/download.

2. U.S. Department of Health and Human Services, Food and Drug Administration. S6(R1) preclinical safety evaluation of biotechnology-derived pharmaceuticals. Accessed August 09, 2021. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/s6r1-preclinical-safety-evaluation-biotechnology-derived-pharmaceuticals.

3. U.S. Department of Health and Human Services, Food and Drug Administration. S9 nonclinical evaluation for anticancer pharmaceuticals. Accessed November 19, 2021. https://www.fda.gov/media/73161/download.

4. Recommendations from a global cross-company data sharing initiative on the incorporation of recovery phase animals in safety assessment studies to support first-in-human clinical trials

5. Appropriate Use of Recovery Groups in Nonclinical Toxicity Studies: Value in a Science-Driven Case-by-Case Approach

Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3